Abstract A randomized double-blind trial comparing the a-adrenergic blocker doxazosin and the /3-adrenergic blocker atenolol was completed by 131 patients with mild to moderate hypertension. Blood pressure and fasting blood lipids were determined at baseline and 4, 12, and 24 weeks of treatment. At entry, plasma lipids and lipoproteins were similar in those patients randomized to doxazosin or atenolol. After 24 weeks of treatment with atenolol, there were significant (P<.05) decreases in high-density lipoprotein cholesterol (HDL-C) and increases in triglycerides and very-low-density triglycerides (VLDL-T). In contrast, doxazosin was associated with significant (P<.05) increases in HDL-C and decreases in triglycerides and VLDL-T. There were no significant differences in HDL apolipoprotein (apo) A-I or low-density lipoprotein apoB between the drugs, but atenolol decreased the
D
emonstration of an adverse effect on serum lipids by some antihypertensive agents (for reviews see References 1 through 5) has focused attention on the actions of antihypertensive drugs other than their blood pressure-lowering properties. Although not proved, it has been suggested that the adverse effect on lipids may offset some of the beneficial effects of reducing cardiovascular risk with antihypertensive drug treatment. Recent advances in the consideration of lipids as risk factors have redefined lipid abnormalities according to lipoprotein levels or apolipoprotein phenotypes. Elevated apolipoprotein B (apoB) levels and reduced apoA-I appear to be independent factors predicting coronary atherosclerosis. 68 Furthermore, patients with myocardial infarction more commonly have the apoE4 allele than the apoE2 allele. 9 The changes in apolipoproteins with some antihypertensive therapy have been examined in less detail compared with the effects on serum lipids. Furthermore, whether these lipoproteins are predictive of the response to antihypertensive drug treatment is not certain. In other words, do serum apolipoprotein levels identify individuals with different lipid responses to antihypertensive drug treatment? The potential interaction of lipids and blood pressure raises the question of whether or not 16 mg or until diastolic blood pressure decreased to below 90 mm Hg on two visits. The initial daily dose of atenolol was 50 mg. The protocol specified at the subsequent 2-week intervals that the doses were to be 50, 50, 100, and 100 mg. If signs or symptoms of adverse effects occurred, the dose was decreased to the next lower level or to the level that was maximally tolerated. The maintenance phase was a 24-week treatment and observation period with assessments every 4 weeks of weight, blood pressure, routine laboratory data, adverse effects, and compliance. The composition of the participants' diets, which would have included dietary cholesterol and fat, were not assessed at baseline or monitored during the study. The underlying assumption was that the randomization strategy would result in similar dietary modifications during the course of the study in both treatment groups.
Inclusion criteria were men 18 to 70 years of age or women 18 to 70 years of age who were postmenopausal or who had undergone surgical sterilization. Patients were diagnosed with mild to moderate hypertension, ie, sitting diastolic blood pressure of 95 to 115 mm Hg while on no other antihypertensive medications.
Exclusion criteria included the following: (1) grade III or IV retinopathy, malignant or known secondary hypertension including estrogen-dependent hypertension, cerebrovascular accident within 1 year, or concurrent therapy with antihypertensives, vasoactive agents including tricyclic antidepressants, or hypolipidemic drugs; (2) lipid disorders that, in the opinion of the investigators, required treatment or serum cholesterol greater than the 90th percentile for age and sex; (3) myocardial infarction within the previous 3 months, sinus bradycardia, angina pectoris requiring prophylactic treatment, or congestive heart failure; (4) concurrent serious illnesses; (5) pregnancy, lactation, or possibility of pregnancy; (6) intention to donate blood during or within 1 month of completion of the study; (7) allergic rhinitis, bronchial asthma, peripheral vascular disease, or chronic obstructive pulmonary disease requiring drug treatment; (8) documented history of lack of response to a,-or /J-adrenergic blocking drugs; and (9) documented or clinically suspected serious adverse reaction to a,-or /3-adrenergic blocking drugs. One hundred ninety-one patients were enrolled in the trial and randomized to either atenolol (n=95) or doxazosin (n=96). There were more dropouts in the doxazosin group, the details of which have been provided. 10 Of the patients completing the trial on atenolol (n=75) 76% were on 50 mg/d and 24% were on 100 mg/d, and of the patients completing the trial on doxazosin (n=56) 32.1% were on 1 mg/d, 5.4% on 2 mg/d, 12.5% on 4 mg/d, 10.7% on 8 mg/d, and 39.3% on 16 mg/d.
All study medications were presented in double-blind, identical capsules. Blood pressure was measured with a standard mercury sphygmomanometer using phase I Korotkoff sounds for systolic blood pressure and the fifth Korotkoff sounds for definition of diastolic blood pressure. The procedure for blood pressure determination followed recommended protocols."
Routine laboratory data included a complete blood count, electrolytes, creatinine, bilirubin, serum proteins, albumin, alkaline phosphatase, serum glutamic-oxaloacetic transaminase, and fasting blood sugar.
Lipid and Lipoprotein Measurements
Four blood samples were taken from each patient. One sample was taken at the end of the evaluation period, and the subsequent three were taken during the maintenance phase of the study (weeks 4, 12, and 24). Fasting blood samples (12 to 14 hours) were collected in tubes containing EDTA-K 3 (1.5 mg/mL) and 0.002 mg potassium sorbate. Samples were stored at 4°C and centrifuged to separate blood cells within 1 hour at 1500g for 30 minutes. Plasma was transferred to a labeled polypropylene transporting vial, sealed, and shipped the same day by overnight courier in a Styrofoam box containing cold packs; 96.3% of samples arrived the day after blood sampling, and 3% arrived 2 days after sampling. Sam, or more after sampling were redrawn and r day of arrival, aliquots of each plasma sampK analyses of total cholesterol and total triglyceric 5 mL plasma from each sample was subjected t > ugation. Plasma was overlayered with d> 1.006 g, tant (containing 0.15 mmol/L NaCl, 1 mmol/L EL ^2, 1 mmol/L Tris [pH 7.4], 3 mmol/L sodium azide, O.i. mmol/L thimerosol, and 10 mol/L phenylmethylsulfonyl fluoride) and centrifuged in a Beckman 50.3 Ti rotor for 16 hours at 40K, 12°C. Very-low-density lipoprotein cholesterol (VLDL-C) was recovered by tube slicing and the infranatant carefully recovered and adjusted to 5 mL. Aliquots from the infranatant were taken for determination of cholesterol, triglycerides, highdensity lipoprotein cholesterol (HDL-C), apoB, and apoA-I. Samples were stored at -80°C until assayed.
The VLDL from the first sample from each patient was assayed for apoE phenotype by analytic isoelectric focusing gel electrophoresis. 12 Cholesterol and triglycerides were assayed using enzymatic reagents obtained from Boehringer-Mannheim (cholesterol: CHOD-PAP; triglycerides: triglycerides without free glycerol). HDL-C was determined from the d> 1.006 g/mL infranatant after precipitation by dextran sulfate/magnesium chloride. 13 Low-density lipoprotein cholesterol (LDL-C) was determined by subtracting HDL-C from the d> 1.006 g/mL infranatant cholesterol value. VLDL-C was determined as the difference between total and infranatant cholesterol. The intra-assay and interassay coefficients of variation for total cholesterol were 2.2% and 3.0%, respectively; for HDL-C, 2.8% and 3.5%, respectively; and for total triglycerides, 2.5% and 3.6%, respectively.
ApoB and apoA-I were assayed by modifications of the rocket immunoelectrophoresis assay of Laurell.
14 ApoB was assayed as described by Reardon et al" after lipase treatment in the presence of fatty acid-free albumin. ApoA-I was assayed essentially as described by Fidge et al, 16 with the exception that the buffer contained Triton X-100. ApoB and apoAl were measured in the d> 1.006 g/mL infranatant. Values were taken as representing LDL apoB and HDL apoA-I, respectively. The intra-assay and interassay coefficients of variation for apoB were 4.5% and 8% and for apoA-I were 3.8% and 7.2%, respectively. For each lipid and apolipoprotein parameter, all samples for each patient were assayed in duplicate in the same assay, thus avoiding interassay variation. All assays were standardized to plasma secondary standards for which target values were assigned by the Lipid Research Clinic (LRC) Laboratory, University of Toronto, St Michael's Hospital, Toronto, Canada. The Toronto LRC is standardized by the Centers for Disease Control and Prevention, Atlanta, Ga.
Statistical Evaluation
For each patient the initial analysis focused on the total change in the lipid parameters from baseline levels, recorded during the evaluation/placebo phase, to the final value at the end of the maintenance phase. As these changes were approximately normally distributed, based on an investigation of the data for all patients, the relevant normal theory statistical methods were used for comparison: / test, ANOVA, and ANCOVA. In addition, repeated-measures designs were used to investigate the patterns of changes over time, using all the measurements made over the maintenance period. The first step examined the hypothesis that changes in plasma lipid levels are seen with treatment by antihypertensive drugs. All patients who completed the trial were used to test this hypothesis. Next, the average change in lipid levels was compared between the two treatment groups (doxazosin and atenolol). The sample size of the study was designed to detect a difference in the lipid parameters of 10%, assuming a coefficient of variation of 20% or less, a power of 80%, and a significance level (a) of .05. An attrition rate of 20% was built into the sample size calculations. Thus, a change in lipid value of greater than or equal to 10% was within the range anticipated. The third hypothesis was that dose-response models determine whether changes in levels of lipid parameters are a function of the daily dose given during the maintenance phase. This is, by definition of the study protocol, the dose required to control the patient's diastolic blood pressure. Linear regression analysis was used because appropriate normal distribution assumptions held, and each treatment group was investigated separately. The fourth hypothesis was that the blood pressurelowering effects are independent of their effect on lipids. In part, this was answered by testing the previous hypothesis, ie, if similar blood pressure but dissimilar lipid effects are observed. In addition, blood pressure was considered as a covariate relating lipid response to drug dose in ANCOVA. The fifth hypothesis was that the initial LDL apoB or ratio of LDL-C to apoB predicts the lipid responses during treatment with antihypertensive drugs. This was examined by dividing patients into groups according to apolipoprotein distribution. Blood pressure and lipid responses to antihypertensive treatment were assessed by ANOVA with the antihypertensive drug treatment as the covariate. The last hypothesis was that patients defined by apoE phenotype determine whether the response to the drug is different. ANCOVA was used to investigate this question. It was decided a priori that subgroups would be joined together when particular subgroups were too small.
Results
Lipids Table 1 shows the baseline data for the 131 patients who completed the trial. At baseline, there were no significant differences between plasma cholesterol, HDL-C, LDL-C, triglycerides, VLDL-C or VLDL triglycerides (VLDL-T), the ratios of LDL-C to HDL-C and VLDL-C to VLDL-T, HDL apoA-I, LDL apoB, or the ratios of LDL-C to apoB and HDL-C to apoA-I in those patients randomized to doxazosin or atenolol. The ratios were calculated because of suggestions that some of them may be more predictive of the risk of coronary atherosclerotic heart disease.
Over the 6 months of treatment, total cholesterol decreased significantly (P<.05) in the doxazosin-but not the atenolol-treated group compared with baseline levels. HDL-C significantly (P<.05) decreased in the atenolol and increased in the doxazosin group, and total triglycerides and VLDL-T increased significantly (P<.05) in the atenolol but decreased in the doxazosin group. There were no significant changes in body weight in either group and no significant (P=.449) differences in the change in body weight between the atenolol group (-0.014±3.871 kg) and the doxazosin group (0.461±3.132 kg) from baseline to the end of the study.
Comparison of the doxazosin-with the atenolol-treated groups showed highly significant differences in HDL-C, triglycerides, VLDL-T, VLDL-C, and the ratio of HDL-C to HDL apoA-I at 1, 3, and 6 months of treatment ( Table 2) . Compared with the atenolol group, HDL-C was significantly (P<.05) higher in the doxazosin group at all three visits (4,12, and 24 weeks after treatment). VLDL-T were significantly lower in the doxazosin group. The differences in VLDL-C during treatment between the two drugs were not as marked but were significant at both 4 and 24 weeks of follow-up. There were few other significant differences (Table 3) .
There were no consistent differences in HDL apoA-I or LDL apoB between the two treatment groups over the 24-week observation period, although there were significant differences in LDL apoB and the ratio of LDL-C to apoB in the doxazosin compared with the atenolol group at 4 weeks but not thereafter (Table 4) . Although there were no significant differences in HDL apoA-I itself, there was a significantly higher ratio of HDL to apoA-I observed in the doxazosin compared with the atenolol patients. Considering the changes in lipoproteins from baseline, the ratio of HDL-C to apoA-I increased in doxazosin-treated patients and fell with atenolol treatment; the differences were consistently noted and highly significant at 4,12, and 24 weeks of treatment.
Interrelation of Blood Pressure and Lipids
The differences in the effect of doxazosin and atenolol on lipids were independent of their effects on blood pressure. When systolic blood pressure was considered in ANCOVA, the differences between the two drugs remained significant in their effect on HDL-C (P=.000l), the ratio of HDL-C to total cholesterol (/>=.0001), triglycerides (/> = .0001), VLDL-C (/>=.O322), and VLDL-T (/>=.0001). When diastolic blood pressure was considered in ANCOVA, the differences between the two drugs remained significant in their effect on HDL-C (/ ) =.0002), the ratio of HDL-C to total cholesterol (/ > =.0001), triglycerides (Z'=.0001), VLDL-C (P=.O37O), and VLDL-T (P=.0001). Furthermore, there was little effect of considering blood pressure in the analysis. There were no significant doseresponse relations between antihypertensive drug and changes in lipids or lipoproteins.
ApoE
The dominant phenotype for apoE in the population of hypertensive patients screened for entry to this study Definitions are as in Table 1 . Values are mean±SD and expressed in millimoles per liter (except for apolipoproteins, in milligrams per deciliter). Mean cholesterol, HDL-C, and triglycerides only have been previously reported 10 and are included here for completeness of presentation of lipid data. Differences between treatments were determined by repeated-measures ANOVA.
•Doxazosin vs atenolol. tMolar ratios. Weight ratios.
was apoE3/3, which occurred in 64.7% (n=124) of the group; the next major phenotype was apoE4/3 in 20.5% (n=39), then apoE3/2 in 11.6% (n=22), followed by apoE4/4 in 1.6% (n=3) and apoE4/2 in 1.0% (n=2). The relation between apoE phenotype and baseline lipids was examined comparing the three major apoE phenotypes (Table 5 ). Significant differences were seen for LDL-C, being higher in carriers of the apoE3/3 and 4/3 phenotypes, and for triglycerides, which were higher in the E3/2 carriers. Dichotomizing the patient to the presence or absence of the apoE4 phenotype did not reveal any significant differences in the lipids. Dichotomizing them according to whether or not they had apoE3 showed that those with apoE3 had significantly lower triglyceride values (1.68 versus 2.57 mmol/L, / ) =.0357) and VLDL-T (1.24 versus 2.04 mmol/L, / > =.O442) but no other lipid differences. Repeatedmeasures ANOVA was used to examine the effect of apoE phenotypes on the lipid responses to drugs using three different considerations of apoE phenotyping. Comparisons of the apoE3/2 versus E3/3 versus E4/3 or apoE4 versus non-E4 or apoE3/3 versus E3/2 plus E4/3 were performed. The significant differences in lipid response remained, although apoE influenced to some extent the strength of the association between the different drugs and the changes in HDL-C (Table 6 ).
ApoA-I and ApoB as Predictors of the Lipid Response to Antihypertensive Drug Therapy
To test the hypothesis that initial HDL apoA-I or LDL apoB predicts the response to antihypertensive drugs, these apolipoproteins were divided into the lower and higher 50th percentile. No significant differences were found between individuals in the upper or lower percentile with respect to any of the lipid or lipoprotein responses to treatment.
Discussion
Little doubt exists about the atherogenic potential of elevations of serum cholesterol transported in LDL. This conclusion is based on epidemiological, experimental, and clinical trial data as well as genetic entities such as familial hypercholesterolemia. The risk of fatal or nonfatal coronary artery disease increases with increasing levels of serum cholesterol in men and women.
1719 HDL-C is inversely related to the development of clinical manifestations of coronary artery disease 20 as well as the presence of angiographic evidence of coronary disease. 21 Triglycerides are also a risk factor for development of coronary artery disease in some people, 22 -23 especially in the setting of low HDL-C. Favorable modification of serum triglycerides and HDL-C reduces the occurrence of coronary disease events. Thus, the effect of antihypertensive treatment on serum Iipids is of considerable potential importance. The present study examined several a priori hypotheses. It found significant differences in Iipids, closely linked to the risk of development of atherosclerosis, during treatment with two antihypertensive drugs. Each agent lowered blood pressure to a similar degree. 10 HDL-C was significantly higher, and total triglycerides and VLDL-T were significantly lower in patients treated with doxazosin compared with those treated with atenolol. The ratios of HDL-C to total cholesterol and LDL-C to HDL-C were more favorably affected by doxazosin than atenolol. Some of the changes during treatment were small. Although one can raise questions of the clinical relevance, small differences in some Iipids, notably HDL-C, are associated with meaningful .0002
Definitions are as in Table 1 . Values are mean±SD and expressed as g/LxiOO. Ratios are weight ratios.
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differences in the occurrence of atherosclerotic coronary artery disease. 24 Furthermore, the directions of the changes were sometimes opposite, as doxazosin increased and atenolol decreased HDL-C. In other studies, triglycerides were invariably increased by atenolol, whereas the effect on cholesterol has been variable and usually not statistically significant. The effects of doxazosin on lipids have not been as extensively investigated. Poole 37 reported a significant decrease in total triglycerides and an increase in HDL-C and the ratio of HDL-C to total cholesterol with doxazosin compared with placebo. Trost et al 38 compared doxazosin with hydrochlorothiazide and found a reduction in triglycerides and total cholesterol with doxazosin after 24 weeks of active treatment compared with an increase with hydrochlorothiazide. HDL-C was increased with doxazosin and reduced with hydrochlorothiazide. Ferrara et al 39 compared doxazosin with captopril in an open parallel study in hypercholesterolemic hypertensive patients and found decreases in cholesterol and triglycerides and increases in HDL-C with doxazosin. Only the change in HDL-C was significantly different from captopril. In the Treatment of Mild Hypertension Study (TOMHS), 40 doxazosin was associated with reductions in total triglycerides and cholesterol and increases in HDL-C, but the nutritional and hygienic advice given to participants in .0327
.0597
.0001
. that study was associated with significant weight loss that would be anticipated to affect these lipids. Several trials have compared doxazosin with atenolol. They usually had smaller numbers of patients or shorter durations of follow-up compared with the present study. Findings include significant increases in HDL-C and decreases in triglycerides with doxazosin compared with reductions in HDL-C and increases in triglycerides with atenolol. 4146 Previous studies of lipids during the treatment of hypertension with atenolol and/or doxazosin have usually not included detailed lipid analyses. Few studies directly measured VLDL-C, VLDL-T, and LDL-C, whereas the present study determined these values directly after ultracentrifugation. LDL-C is the most atherogenic component of total cholesterol and is most strongly related to coronary disease risk. These levels can be calculated, 47 but are more precisely determined by actual measurements through ultracentrifugation. Thus, some of the differences among previous studies may have been due to extrapolations rather than direct measurement.
An important contribution of the present study is that it examined the effects of atenolol and doxazosin treatment on apolipoproteins. ApoA-I is the principal constituent of HDL. HDL is associated with enhanced efflux of cholesterol from the arterial wall, and thus high levels of HDL-C, particularly HDL 2 , are associated with a decreased risk of atherosclerosis. 48 Decreased plasma concentrations of apoA-I have been associated with premature coronary artery disease 7 ' 49 -50 and considered by some investigators to be a better discriminator than plasma cholesterol, triglycerides, or HDL-C for identifying patients with coronary artery disease. 7 In the present study there were no significant differences in apoA-I between atenolol and doxazosin treatment. However, considering apoA-I with HDL-C by the ratio of HDL-C to apoA-I did magnify the differences between the groups, and highly significant differences were observed. The increased ratio of HDL-C to apoA-I with doxazosin suggests a shift toward the less atherogenic HDL 2 particles, 51 although the composition of the apoA-I particle rather than HDL 2 is likely a more important consideration for atherogenicity. In contrast, there were no changes in apoB, which is produced either in the liver in association with VLDL-C and LDL-C or in the intestine where it is associated with chylomicrons. 52 Increases in apoB levels have been found to be associated with premature coronary atherosclerosis. 6 -7 - 53 There were no significant differences in the effects of atenolol or doxazosin on LDL apoB. Nadeau et al 34 suggested that atenolol may increase total serum apoB and decrease total serum apoA-I, and Houston et al 54 reported no significant changes in either of these two apolipoproteins with atenolol. Ferrara et al 39 reported no changes in apoA-I or apoB with doxazosin. In contrast to these previous studies, the present data are based on measurements of apoB in the LDL fraction and apoA-I in the HDL fraction rather than total serum apoA-I or apoB.
Another important contribution of the present study is the examination of apoE phenotypes in a hypertensive population to answer the question of whether or not these phenotypes influence the lipid response to two different antihypertensive drugs. The E apolipoproteins are associated with chylomicrons and VLDL and mediate their binding to LDL and chylomicron remnant receptors. 9 The apoE gene is polymorphic with three common isoforms, E2, E3, and E4, with three homozygote phenotypes -namely apoE2/2, apoE3/3, and apoE4/4 -and three common heterozygote phenotypes -namely, apoE3/2, apoE3/4, and apoE4/2. Homozygosity for apoE2 is associated with type HI hyperlipoproteinemia caused by defective binding of apoE2 to hepatic receptors. However, in the normal lipidemic population, carriers of apoE2 have lower LDL-C, whereas carriers of the apoE4 allele have higher LDL-C concentrations. Most patients in the present study had the apoE3/3 phenotype followed by apoE4/3. No homozygotes for apoE2 were found, and no major alteration in apoE phenotype distribution was observed when compared with previous studies. 9 These data, provided in a hypertensive patient group, with the caveat that the initial entry criteria excluded patients with marked hyperlipidemia, show an apoE distribution similar to that in two studies of normotensive groups in the same country (Table 7) . A further objective of the present study was to examine the effect of apoE phenotype on the lipid response to antihypertensive drug therapy. ApoE phenotype influences the effect of diet on LDL-C and HDL-C levels. 9 - 55 Our a priori hypothesis that the apoE phenotype would be a predictor of the lipid and especially triglyceride or VLDL-T response to antihypertensive treatment with either atenolol or doxazosin was not substantiated by the data even when several different models of apoE phenotyping were considered.
The present study showed that the differences in the effect of doxazosin and atenolol on lipids are independent of their effects on blood pressure. When systolic or diastolic blood pressure was considered in the ANCOVA, the differences between the two drugs in their effect on HDL-C, the ratio of HDL-C to total cholesterol, trigrycerides, VLDL-C, and VLDL-T remained significant. This suggests that blood pressure reduction is not causally linked with changes in lipids and lipoproteins because blood pressure reduction to the same extent was associated with disparate effects on lipids when accomplished by two different agents.
In summary, the present study assessed the effect of antihypertensive treatment on lipids and lipoproteins in patients with mild to moderate hypertension. Changes in blood pressure or concentrations of apoA-I, apoB at baseline, or apoE phenotype were not significant predictors of lipid response to treatment with either the £-blocker atenolol or the a-blocker doxazosin. Doxazosin decreased triglycerides and increased HDL-C, whereas atenolol increased triglycerides and decreased HDL-C. Although neither agent altered apoA-I or apoB, there was a marked increase in the ratio of HDL-C to apoA-I in the doxazosin group, reflecting a shift to less atherogenic HDL 2 particles, which suggests a reduction in coronary atherosclerotic heart disease risk. Taken together with the data on the beneficial effects on coronary atherosclerosis of increased HDL, particularly HDL 2 , and apoA-I, these data highlight the necessity for consideration of the consequences on lipids and lipoproteins of adrenergic drugs in the treatment of some patients with hypertension. No lipid factor is predictive of the changes in lipids that occur during antihypertensive therapy with these agents. 
